CASCADE Publications
As part of the CASCADE study's aim to promote better understanding of effective health planning for people with HIV, insights from the study are disseminated through academic publication.
Please see the publications below from the CASCADE study, in order of date of publication.
2024
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration, Pantazis N, Sabin CA, Grabar S, Van der Valk M, Jarrin I, van Sighem A, Meyer L, Carlander C, Gill J, Volny Anne A, Spire B, Tariq S, Burns F, Costagliola D, Ruiz-Burga E, Touloumi G, Porter K; CASCADE Collaboration.
HIV prevention and missed opportunities among people with recently acquired HIV infection: Α protocol for a systematic review, Karakosta A, Ruiz-Burga E, Tariq S, Touloumi G, Jay Nicholls E, Pantazis N, Jarrin I, Van der Valk M, Sabin C, Mussini C, Meyer L, Volny Anne A, Carlander C, Grabar S, Wittkop L, Spire B, Gill J, Porter K, Burns F; for CASCADE Collaboration.
2023
A systematic review of qualitative research on recently acquired HIV, Nicholls EJ, Policek N, Volny-Anne A, Spire B, Burns F, Ruiz-Burga E, Tariq S; for CASCADE Collaboration.
CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada, Ruiz-Burga E, Tariq S, Touloumi G, Gill J, Nicholls EJ, Sabin C, Mussini C, Meyer L, Volny Anne A, Carlander C, Grabar S, Jarrin I, Van der Valk M, Wittkop L, Spire B, Pantazis N, Burns FM, Porter K; For CASCADE Collaboration.
Archive
HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors, Paraskevis D, Beloukas A, Stasinos K, Pantazis N, de Mendoza C, Bannert N, Meyer L, Zangerle R, Gill J, Prins M, d'Arminio Montforte A, Kran AB, Porter K, Touloumi G; CASCADE collaboration of EuroCoord.
Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort, van Santen DK, van der Helm JJ, Touloumi G, Pantazis N, Muga R, Gunsenheimer-Bartmeyer B, Gill MJ, Sanders E, Kelleher A, Zangerle R, Porter K, Prins M, Geskus RB; CASCADE Collaboration within EuroCoord.
The concordance of the limiting antigen and the Bio-Rad avidity assays in persons from Estonia infected mainly with HIV-1 CRF06_cpx, Huik K, Soodla P, Pauskar M, Owen SM, Luo W, Murphy G, Jõgeda EL, Kallas E, Rajasaar H, Avi R, Masciotra S, Lutsar I; CASCADE Collaboration in the EuroCoord.
Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort, Olson A, Bannert N, Sönnerborg A, de Mendoza C, Price M, Zangerle R, Chaix ML, Prins M, Kran AB, Gill J, Paraskevis D, Porter K; for CASCADE Collaboration in EuroCoord.
Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion, Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, Young J, Bucher HC, Babiker AG; CASCADE Collaboration in EuroCoord.
HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay, Soodla P, Simmons R, Huik K, Pauskar M, Jõgeda EL, Rajasaar H, Kallaste E, Maimets M, Avi R, Murphy G, Porter K, Lutsar I; Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) Collaboration in EuroCoord.
Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection, Fidler S, Olson AD, Bucher HC, Fox J, Thornhill J, Morrison C, Muga R, Phillips A, Frater J, Porter K.
Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection, Mangal TD; UNAIDS Working Group on CD4 Progression and Mortality Amongst HIV Seroconverters including the CASCADE Collaboration in EuroCoord.
Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014, van Santen DK, van der Helm JJ, Del Amo J, Meyer L, D'Arminio Monforte A, Price M, Béguelin CA, Zangerle R, Sannes M, Porter K, Geskus RB, Prins M; CASCADE Collaboration in EuroCoord.
CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus, Ghosn J, Bayan T, Meixenberger K, Tran L, Frange P, d'Arminio Monforte A, Zangerle R, de Mendoza C, Krastinova E, Porter K, Meyer L, Chaix ML; CASCADE Collaboration in EuroCoord.
A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations, Fearnhill E, Gourlay A, Malyuta R, Simmons R, Ferns RB, Grant P, Nastouli E, Karnets I, Murphy G, Medoeva A, Kruglov Y, Yurchenko A, Porter K; Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) Collaboration in EuroCoord.
Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death, Olson AD, Walker AS, Suthar AB, Sabin C, Bucher HC, Jarrin I, Moreno S, Perez-Hoyos S, Porter K, Ford D; CASCADE Collaboration in EuroCoord.
The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment, Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, Lutsar I, Chaix ML, Fisher M, Moreno S, Porter K; CASCADE Collaboration in EuroCoord.
HIV Incidence Estimates Using the Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014, Simmons R, Malyuta R, Chentsova N, Karnets I, Murphy G, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K; CASCADE Collaboration in EuroCoord.
Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?, Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Boufassa F, Costagliola D, Porter K, Blanco J, Del Amo J, Martinez-Picado J; for CASCADE Collaboration in EuroCoord.
HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013-March 2014, Simmons R, Malyuta R, Chentsova N, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K; CASCADE Collaboration in EuroCoord.
Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study, van der Helm JJ, Geskus R, Lodi S, Meyer L, Schuitemaker H, Gunsenheimer-Bartmeyer B, Monforte Ad, Olson A, Touloumi G, Sabin C, Porter K, Prins M; CASCADE Collaboration in EuroCoord.
Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study, Pantazis N, Porter K, Costagliola D, De Luca A, Ghosn J, Guiguet M, Johnson AM, Kelleher AD, Morrison C, Thiebaut R, Wittkop L, Touloumi G; CASCADE Collaboration in EuroCoord.
Joint modeling of HIV data in multicenter observational studies: A comparison among different approaches, Brombin C, Di Serio C, Rancoita PM.
Evaluation of rapid progressors in HIV infection as an extreme phenotype, Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, Moreno S, Porter K; for CASCADE Collaboration in EuroCoord.
An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration, Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord.
Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration, Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study.
Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection, Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K; CASCADE Collaboration in EuroCoord.
Natural history of HIV-control since seroconversion, Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; CASCADE Collaboration in Eurocoord.
High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland, Rosińska M, Marzec-Bogustawska A, Janiec J, Smoleń-Dzirba J, Wąsik T, Gniewosz J, Zalewska M, Murphy G, McKinney E, Porter K; CASCADE Collaboration In Eurocoord.
Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration, Touloumi G, Pantazis N, Chaix ML, Bucher HC, Zangerle R, Kran AM, Thiebaut R, Masquelier B, Kucherer C, Monforte Ad, Meyer L, Porter K; for CASCADE Collaboration in EuroCoord.
Risk of tuberculosis following HIV seroconversion in high-income countries, Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord.
High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults, Simmons R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, Porter K; CASCADE collaboration in EuroCoord.
Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts, Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord.
Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997, van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chêne G, Dorrucci M, Muga R, Porter K, Prins M; CASCADE Collaboration in EuroCoord.
Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts, Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix ML, Bucher HC, Kücherer C, Zangerle R, Kran AM, Porter K; CASCADE collaboration in EuroCoord.
Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection, Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.
Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa, Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, Porter K, Meyer L, Touloumi G; CASCADE Collaboration in EuroCoord and ANRS 1220 Primo-CI Study Group.
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion, Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K.
Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia, Jarrin I, Pantazis N, Gill MJ, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, de Olalla PG, Porter K, del Amo J; CASCADE Collaboration in EuroCoord.
The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007, van der Helm JJ, Prins M, del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, Geskus RB; CASCADE Collaboration.
Decline of CD4⁺ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals, Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucci M; CASCADE Collaboration.
Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters, Writing Committee for the CASCADE Collaboration.
Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults, Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR; CASCADE Collaboration.
Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines, Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.
CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era, Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, Vanhems P, Porter K; CASCADE Collaboration.
Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion, Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K; CASCADE Collaboration.
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy -- the CASCADE collaboration: a collaboration of 23 cohort studies, Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chêne G, Mussini C, Porter K, Bucher HC; CASCADE Collaboration Members.
Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions, Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Balotta C, Back NK, Jorgensen LB, de Mendoza C, Bhaskaran K, Gill ON, Johnson AM, Pillay D; Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) Collaboration.
Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women, Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J; CASCADE Collaboration.
The effect of antiretroviral treatment of different durations in primary HIV infection, Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K; CASCADE Collaboration.
Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice, Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Boufassa F, Vanhems P, Porter K; CASCADE Collaboration.
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy, Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K; CASCADE Collaboration.
Changes in the risk of death after HIV seroconversion compared with mortality in the general population, Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K; CASCADE Collaboration.
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults, Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K; HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS); Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration.
Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART), Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A, on behalf of the CASCADE Collaboration.
Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study, Lampe FC, Porter K, Kaldor J, Law M, Kinloch-de Loes S, Phillips AN; CASCADE Collaboration.
Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load, Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaans S, van der Hoek L; CASCADE collaboration.
Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences, Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K; CASCADE Collaboration.
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion, Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M; CASCADE Collaboration.
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy, Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kücherer C, Poggensee G, Gill J, Porter K; CASCADE Virology Collaboration.
Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion, Thiébaut R, Jacqmin-Gadda H, Walker S, Sabin C, Prins M, Del Amo J, Porter K, Dabis F, Chêne G; CASCADE Collaboration.
Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters, Madec Y, Boufassa F, Porter K, Meyer L; CASCADE Collaboration.
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003, Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jørgensen LB, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kücherer C, Poggensee G, Ortiz M, de Mendoza C, Gill J, Fleury H, Porter K; CASCADE Collaboration.
Joint modelling of bivariate longitudinal data with informative dropout and left-censoring, with application to the evolution of CD4+ cell count and HIV RNA viral load in response to treatment of HIV infection, Thiébaut R, Jacqmin-Gadda H, Babiker A, Commenges D; CASCADE Collaboration.
Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates, Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, Hatzakis A, Porter K; CASCADE Collaboration.
Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors, Bhaskaran K, Brettle R, Porter K, Walker AS; CASCADE Collaboration.
Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era, Phillips A, Pezzotti P; CASCADE Collaboration.
Determinants of survival following HIV-1 seroconversion after the introduction of HAART, Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Walker AS; CASCADE Collaboration.
Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data, Clements M, Law M, Pedersen C, Kaldor J; CASCADE Collaboration.
Impact of tuberculosis on HIV disease progression in persons with well-documented time of HIV seroconversion, Del Amo J, Pérez-Hoyos S, Hernández Aguado I, Díez M, Castilla J, Porter K; Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) Collaboration.
Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion, CASCADE Collaboration.
Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters, Babiker A, Darbyshire J, Pezzotti P, Porter K, Prins M, Sabin C, Walker AS; CASCADE Collaboration.
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks, Babiker A, Darbyshire J, Pezzotti P, Porter K, Cox DR; CASCADE Collaboration.
Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?, Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration).
Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE, CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration.
Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE, CASCADE Collaboration Project.
Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis, Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
Survival after introduction of HAART in people with known duration of HIV-1 infection, The CASCADE Collaboration. Concerted Action on SeroConversion to AIDS and Death in Europe.